|Bid||0.9000 x 0|
|Ask||0.9500 x 0|
|Day's Range||0.8900 - 0.9200|
|52 Week Range||0.2500 - 1.6000|
|Beta (5Y Monthly)||-0.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 16, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.10|
RICHMOND HILL, ON / ACCESSWIRE / April 9, 2021 / Helix BioPharma Corp. (TSX:HBP)(FSE:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received conditional approval from the Toronto Stock Exchange (the "TSX") to extend the exercise period of a total of 2,837,000 outstanding common share purchase warrants (the "Warrants"), all of which are held by arm's length parties.
By John Vandermosten, CFA TSX:HBP.TO | OTC:HBPCF READ THE FULL HBP.TO RESEARCH REPORT Second Quarter Fiscal Year 2021 Operational and Financial Results Helix BioPharma Corp. (TSX:HBP.TO) (OTC:HBPCF) reported 2Q:21 financial and operational results and submitted its SEDAR filings on March 16, 2021. During fiscal 2Q:21, the three months ended January 31, 2021, Helix executed a definitive agreement
RICHMOND HILL, ON / ACCESSWIRE / March 16, 2021 / Helix BioPharma Corp. (TSX:"HBP"), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal second quarter ended January 31, 2021.